Bolus and continuous infusion mitoxantrone in newly diagnosed adult acute lymphoblastic leukemia: Results of two consecutive phase II clinical studies

Cancer Investigation

Volumn 16, Issue 6, 1998, Pages 355-365

  Koc, Yener ^a   Akpek, Görgün ^a   Kansu, Emin ^a   Kars, Ayse ^a   Tekuzman, Gülten ^a   Baltali, Esmen ^a   Güler, Nilüfer ^a   Barista, Ibrahim ^a   Güllü, Ibrahim ^a   Ozisik, Yavuz ^a   Firat, Dincer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BOLUS INJECTION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031904216     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809115774     Document Type: Article

References (49)

1. Copelan EA, McGuire EA: The biology and treatment of acute lymphoblastic leukemia in adults. Blood 85:1151-1168, 1995.
2. Hoelzer D, Gale RP: Acute lymphoblastic leukemia in adults: Recent progress, future directions. Semin Hematol 24:27-39, 1987.
3. Kantarjian HM, Walters RL, Keating MJ, et al: Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65:5-8, 1990.
4. Kantarjian HM, Walters RS, Keating MJ, et al: Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with Address correspondence and reprint requests to: Yener Koc, M.D., Tufts University School of Medicine, New England Medical Center, Bone Marrow Transplant Service, 750 Washington Street, NEMC #542, Boston, MA 02111. standard and high-risk acute lymphoblastic leukemia. J Clin Oncol 8:994-1004, 1990.
5. Arlin ZA, Feldman EJ, Finger LR, et al: Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 5:712-714, 1991.
6. Hoelzer D, Thiel E, Ludwig WD, et al: Follow-up of the first two successive German multicenter trials for adult ALL (01/81 and 02/84). German Adult ALL Study Group. Leukemia 7(Suppl 2):S130-134, 1993.
7. Murdock KC, Child RG, Fabio PF, et al: Antitumor agents. 1. 1, 4Bis [(aminoalkyl)amino] 9, 10-anthracenediones. J Med Chem 22:1024-1030, 1979.
8. Paciucci PA, Cuttner J, Holland JF, et al: Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 1 l(SuppI 1):36-40, 1984.
9. Hiddemann W, Buchner TH, Heil G, et al: Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 4:637-640, 1990.
10. Benjamin RS: Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 22(Suppl 1):11-13, 1995.
11. Michelutti A, Damiani D, Michieli A, et al: Comparative toxicity of mitoxantrone, idarubicin and doxorubicin in sensitive and multidrug resistant human tumor cell lines. Haematologica 76(Suppl 4):76, 1991.
12. Greidanus J, de Vries EG, Mulder NH, et al: A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 7:790-797, 1989.
13. Bennett JM, Catovsky D, Daniel MT, et al: The FrenchAmerican-British (FAB) Cooperative Group. The morphologic classification of acute lymphoblastic leukemia: Concordance among observers and clinical correlation. Br J Haematol 47:553-561, 1981.
14. Link MP, Warnke RA, Finlay J, et al: A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies. Blood 62:722-728, 1983.
15. Sobol RE, Mick R, Royston I, et al: Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med 316:1111-1117, 1987.
16. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981.
17. Zubrod CG, Schneiderman M, Frei E, et al: Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J ChronDis 11:7-33, 1960.
18. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457, 1958.
19. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966.
20. Paciucci PA, Ohnuma T, Cuttner J, et al: Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 43:3919-3922, 1983.
21. Moore JO, Olsen GA: Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol ll(Suppl 1):41-46, 1984.
22. Arlin ZA, Silver R, Cassileth P, et al: Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 69:61-64, 1985.
23. Hiddemann W, Kreutzmann H, Straif K, et al: High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14(Suppl l):73-77, 1987.
24. Paciucci PA, Keaveney C, Cuttner J, et al: Mitoxantrone, vin-cristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia. Cancer Res 47:5234-5237, 1987.
25. Bezwoda WR, Bernasconi C, Hutchinson RM, et al: Mitoxantrone for refractory and relapsed acute leukemia. Cancer 66:418-122, 1990.
26. Lejeune C, Tubiana N, Gastaut JA, et al: High dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. Eur J Haematol 44:240-243, 1990.
27. Milpied N, Gisselbrecht C, Harousseau JL, et al: Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy. Cancer 66:627-631, 1990.
28. Annino L, Giona F, Vegna ML, et al: Mitoxantrone in adult acute lymphoblastic leukemia (ALL): results of a salvage regimen in primary refractory patients. Haematologica 76(Suppl 4):53, 1991.
29. Arlin ZA, Feldman EJ, Finger LR, et al: Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 5:712-714, 1991.
30. Hiddemann W: High-dose cytosine-arabinoside and mitoxantrone (HAM) in the treatment of acute leukemias: results of salvage and first line treatment. Haematologica 76 (Suppl 4):53, 1991 (abstract).
31. Keating MJ, Kantarjian H, O'Brien S, et al: The M.D. Anderson Cancer Center experience with mitoxantrone in acute leukemia. Haematologica 76(Suppl 4):52, 1991 (abstract).
32. Morra E, Lazzarino M, Pagnucco G, et al: Mitoxantrone with intermediate or high dose Ara-C for refractory acute lymphoblastic leukemia and lymphoma. Haematologica 76(Suppl 4):53, 1991.
33. Sousa A, Fernandes J, Mesquita V, et al: High-dose Ara-C and mitoxantrone in relapsed and refractory acute leukemia. Haematologica 76(Suppl 4):125, 1991.
34. Liso V, Specchia G, Capalbo S, et al: Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia. Acta Haematol 87:54-57, 1992.
35. Feldman EJ, Alberts DS, Arlin Z, et al: Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11:2002-2009, 1993.
36. Schiller G, Lee M, Territo M, et al: Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia. Am J Hematol 43:195-199, 1993.
37. Keskin A, Tombuloglu M, Atamer MA, et al: Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. Acta Haematol 92:14-17, 1994.
38. Cuttner J, Mick R, Budman DR, et al: Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: A CALGB Study. Leukemia 5:425-431, 1991.
39. Weiss M, Maslak P, Feldman E, et al: Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 14:2480-2485, 1996.
40. Benjamin RS: Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 22(SuppI 1):11-13, 1995.
41. Schauer P, Arlin ZA, Mertelsmann R, et al: Treatment of acute lymphoblastic leukemia in adults: Results of the L-10 and L-10M protocols. J Clin Oncol I:462t70, 1983.
42. Hussein KK, Dahlberg S, Head D, et al: Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation and maintenance chemotherapy. Blood 73:57-63, 1989.
43. Linker CA, Levitt LJ, O'Donnell M, et al: Treatment of acute lymphoblastic leukemia in adults with intensive cyclical chemotherapy. Blood 74(Suppl 1):288, 1989.
44. Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 85:2025-2037, 1995.
45. Hoelzer D, Ludwig WD, Thiel E, et al: Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 87:495-508, 1996.
46. Niemeyer CM, Hitchcock-Bryan S, Sallan SE: Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. Semin Oncol 12:122-130, 1985.
47. Ludescher C, Eisterer W, Hübe W, et al: Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia 9:350-356, 1995.
48. Sparano JA, Wiernik, PH, Leaf A, et al: Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 11:1071-1079, 1993.
49. Kantarjian HM, Walters RS, Keating MJ, et al: Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol 8:994-1004, 1990.